2 Growth Stocks to Invest $1,000 in Right Now

Despite lagging the broader market this year, Intuitive Surgical (ISRG) and Vertex Pharmaceuticals (VRTX) are presented as compelling growth investments. Intuitive Surgical, down 16% partly due to tariffs, maintains its dominant position in surgical robotics, driven by an expanding da Vinci system installed base and recurring revenue from procedure-linked accessory sales, underpinned by a strong economic moat. Vertex Pharmaceuticals, though impacted by recent clinical setbacks, boasts a robust cystic fibrosis franchise and a growing pipeline, including the approved non-opioid pain therapy Journavx and the promising investigational type 1 diabetes treatment zimislecel, positioning both companies for significant future growth.

Analysis

Intuitive Surgical (ISRG) has experienced a 16% year-to-date decline, attributed partly to initial tariff impacts on its financial results. Despite this, the company maintains an undisputed leadership position in surgical robotics, driven by a growing installed base of its da Vinci system and the recent launch of its fifth-generation platform. This market dominance is underpinned by a strong economic moat, characterized by high switching costs for healthcare facilities.

ISRG's business model generates predictable, recurring revenue from specialized instruments and accessories, which are essential for procedures and scale with increasing procedure volumes. The company has identified several strategies to address tariff challenges, including negotiation, manufacturing relocation, and leveraging its pricing power to pass on cost increases.

Vertex Pharmaceuticals (VRTX) has also seen its shares decline due to recent clinical setbacks. However, its core cystic fibrosis (CF) product franchise continues to generate increasing sales and profits, providing a robust financial foundation. The company is actively expanding its pipeline to diversify future revenue streams.

VRTX's pipeline includes the recently approved non-opioid acute pain therapy, Journavx, which is gaining traction with third-party payers. Additionally, promising investigational therapies like zimislecel for Type 1 Diabetes, showing potential to restore insulin production, and Casgevy for rare blood diseases, are expected to contribute significantly to future top-line growth.

Key Decisions for Investors

• Consider accumulating positions in Intuitive Surgical (ISRG), leveraging its strong economic moat, recurring revenue streams, and market leadership despite short-term tariff-related pressures.
• Evaluate Vertex Pharmaceuticals (VRTX) for long-term growth, supported by its robust and expanding cystic fibrosis franchise and a diversified pipeline with significant potential in non-opioid pain and Type 1 Diabetes.
• Monitor the effectiveness of Intuitive Surgical's tariff mitigation strategies and key clinical trial readouts for Vertex Pharmaceuticals' pipeline candidates as potential catalysts for share price appreciation.